Tarceva.net

Tarceva mechanism of action

EGFR mutation-positive and wild-type NSCLC are two genetically distinct diseases.^1,2 Tarceva blocks the ATP binding pocket of the EGF receptor in both cases, but its binding capabilities differ.^3,4 The new mechanism of action materials provide the latest hypothesis for the efficacy of Tarceva in EGFR Mut+ and wild-type NSCLC.

 

Tarceva mechanism of action animation Download

Dosing guidelines and management of side effects

Information on dosing and management of side effects (rash, diarrhea and ILD) are summarized in the document “Tarceva: dosing guidelines and side effect management strategies”

Download

Tarceva slide decks

• First-line erlotinib in EGFR Mut+ advanced NSCLC - view
• Erlotinib as maintenance therapy in advanced NSCLC - view
• Second-line erlotinib in patients with advanced NSCLC - view